Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer
In real-world setting, ARPI treatment performs comparable to docetaxel chemotherapy in mHSPC. Therefore, docetaxel should only be used in triplet therapy. Moreover, no differences for sequential therapies of ARPI/docetaxel combinations in first-line mCRPC were observed.
Authors
- Luis Kluth
- Markus Graefen
- Felix K.‐H. Chun (ORCID: https://orcid.org/0000-0001-8486-9536)
- Carolin Siech (ORCID: https://orcid.org/0000-0002-5460-4171)
- Thomas Steuber (ORCID: https://orcid.org/0000-0001-6963-6611)
- Miriam I. Traumann
- Clara Humke
- Philipp Mandel (ORCID: https://orcid.org/0000-0002-0760-7281)
- Mike Wenzel (ORCID: https://orcid.org/0000-0002-4338-0889)
- Cristina Cano Garcia (ORCID: https://orcid.org/0000-0002-4829-0241)
- Benedikt Hoeh (ORCID: https://orcid.org/0000-0002-4238-6584)
Institutions
- Goethe University Frankfurt (DE)
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
- University Hospital Frankfurt (DE)
Publication Details
- Journal
- World Journal of Urology
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1007/s00345-024-05388-1
- Citations
- 6
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.51